Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5837836 | 0.84 | SLC6A2 (0.52) | SLC6A2SLC6A4CACNA1BPDE4BBDKRB1 | |
| SCHEMBL5837839 | 0.84 | SLC6A2 (0.52) | SLC6A2SLC6A4CACNA1BPDE4BBDKRB1 | |
| SCHEMBL5837841 | 0.84 | SLC6A2 (0.52) | SLC6A2SLC6A4CACNA1BPDE4BBDKRB1 | |
| SCHEMBL5718108 | 0.83 | ALDH1A1 (0.49) | SLC6A2SLC6A4ALDH1A1CYP3A4NAAA | |
| SCHEMBL6735711 | 0.83 | SLC6A2 (0.47) | SLC6A2SLC6A4ALDH1A1PDE4BFKBP1A | |
| SCHEMBL5838942 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A4PDE4BBDKRB1 | |
| SCHEMBL5718080 | 0.80 | SLC6A2 (0.52) | SLC6A2SLC6A4CACNA1BPDE4BBDKRB1 | |
| SCHEMBL6731983 | 0.78 | SLC6A2 (0.54) | SLC6A2SLC6A4PDE4B | |
| SCHEMBL5838994 | 0.73 | SMN1; SMN2 (0.47) | SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL11932080 | 0.72 | SLC6A3 (0.41) | SLC6A2ALDH1A1CACNA1BELANECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074780-B2 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20040122004-A1 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122004-A1 | Substituted phenylcyclohexanecarboxamides and their use | TNNI3, PAH, P4HA1 | SLC6A2 1862/4885SLC6A4 2786/4885ALDH1A1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.